Reason for OTC: based on the entire cohort (66 had OTC, the rest had GnRH agonist treatment only): hematological cancer: n=77 (48.4%), gynecological cancer: n=48 (30.2%), soft tissue sarcoma: n=16 (10.1%), gastro intestinal cancer: n=6 (3.8%), miscellaneous: n=12 (7.5%) (neuroblastoma, medulloblastoma, thymoma, adrenocortical carcinoma, glioma, mesothelioma)Reason for AOTT: not specified. Here, GNRH1 is linked to soft tissue sarcoma.